The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / HCQ/CQ May Increase the Risk of Cardiovascular Events

HCQ/CQ May Increase the Risk of Cardiovascular Events

December 1, 2021 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Introduction & Objectives

Both hydroxychloroquine (HCQ) and chloroquine (CQ) are used for the treatment of specific rheumatic and dermatologic diseases. HCQ and CQ were initially developed for treating malaria and have been used since 1955 and 1935, respectively. The most frequent rheumatic diseases for which these medications are used include systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). They are also used to treat discoid and subacute cutaneous lupus erythematosus, as well as dermatomyositis and other autoimmune skin conditions. Based on actual body weight, recommended HCQ and CQ dosing in rheumatic disease patients is ≤5 mg/kg/day and ≤2.3 mg/kg/day, respectively. Higher doses are associated with increased retinal toxicity.

You Might Also Like
  • Biologics May Prevent Cardiovascular Events in RA Patients
  • HCQ Prolongs QT Interval in Patients with COVID-19
  • Depression May Increase Risk of Cardiovascular Disease for RA Patients
Explore This Issue
December 2021

Although arrhythmias and conduction system abnormalities, as well as cardiomyopathy, have been rarely reported in association with HCQ/CQ use, this white paper reviewed and summarized the current understanding of HCQ/CQ cardiac toxicity, describing factors that may increase the risk of HCQ/CQ-associated QTc prolongation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

What the Studies Say

Recent studies, as well as earlier case reports, have shown QTc prolongation with HCQ or CQ at conventional doses used to treat rheumatic disease.

In a Veterans Administration study of more than 800 patients with rheumatic disease (90% male and 10% female) who were taking HCQ and had available electrocardiogram (EKG) data, HCQ was associated with QTc prolongation in 8.5% (7% with QTc 470–500 ms and 1.5% with QTc >500 ms) (37). Among 591 patients in this study who had paired EKG data before and after starting HCQ, 23 patients (3.9%) had either a >15% increase in QTc or a QTc of >500 ms with HCQ treatment. Chronic kidney disease, atrial fibrillation history, and heart failure were independent risk factors for QTc prolongation with HCQ use in the study. While QTc >470 ms with HCQ therapy was associated with long-term mortality in a univariate Cox regression analysis, this increased mortality risk was no longer apparent after adjustment for age, sex, and comorbidities. In patients with paired EKG data, change in QTc was not associated with mortality (hazard ratio 1.001 [95% confidence interval (95% CI) 0.998–1.005], P=0.51).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Both HCQ and CQ accumulate in mammalian lysosomes and cause a more alkaline pH. HCQ and CQ concentrate in the eyes (particularly in the melanin-containing retinal pigment epithelium), adrenal and pituitary glands, kidney, bone marrow, lung, liver and cardiac tissue. This accumulation of drug in lysosomes may confer efficacy in the treatment of rheumatic and cutaneous conditions, but also may be responsible for toxicities, such as atrioventricular (AV) conduction defects and myocardial deposition disease. Although channel blockade tends to be dose dependent and more immediate, cardiac toxicities related to HCQ/CQ deposition require a longer duration of treatment.

Pages: 1 2 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives Tagged With: Arthritis & Rheumatology, cardiovascular, cardiovascular event, chloroquine, Hydroxychloroquine (HCQ), Rheumatoid Arthritis (RA), systemic lupus erythematosus (SLE), toxicityIssue: December 2021

You Might Also Like:
  • Biologics May Prevent Cardiovascular Events in RA Patients
  • HCQ Prolongs QT Interval in Patients with COVID-19
  • Depression May Increase Risk of Cardiovascular Disease for RA Patients
  • Newly Diagnosed SLE Patients Have a Greater Risk of Cardiovascular Disease

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)